Simris Group's wholly-owned subsidiary, Simris Biologics, has signed a non-binding concept sheet with a EU biopharmaceutical company.
The document covers the intention of both parties to explore the possibility of an R&D and licensing agreement involving Simris' proprietary cytotoxin payloads.
Derived from cyanobacteria, the cytotoxin payloads are suitable raw materials for the development of next-generation, novel antibody-drug conjugates (ADCs).
This follows the rise of ADCs in the targeted oncology space.
The concept sheet was created to provide a framework for continued discussions and negotiations, and is non-binding.
The document does not constitute an offer, or create any binding legal obligations between the parties.
“This marks an exciting step in Simris Biologics’ strategy to expand the potential applications of our toxin payloads by partnering with established innovators in targeted cancer therapeutics,” said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB.
“The discussions outlined in the concept sheet are focused on evaluating the integration of Simris’ cyanobacteria-derived payloads into next-generation ADC constructs.”